Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.53 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL670816 | 1.00 | SLC6A4 (0.53) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Maleic Acid SCHEMBL670813 | 1.00 | SLC6A4 (0.53) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Oxalic Acid SCHEMBL669810 | 0.92 | SLC6A4 (0.56) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Oxalic Acid SCHEMBL669809 | 0.92 | SLC6A4 (0.56) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL670256 | 0.90 | SLC6A4 (0.60) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13326771 | 0.90 | SLC6A4 (0.60) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL670486 | 0.90 | SLC6A4 (0.60) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL670771 | 0.90 | SLC6A4 (0.60) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL670098 | 0.90 | SLC6A4 (0.60) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL670097 | 0.90 | SLC6A4 (0.60) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605772-B1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNAT AG (CH) | 2016-06-22 | — | — | EP | claimed |
| US-9006460-B2 | Process for preparing aminocyclohexyl ether compounds | CARDIOME INTERNATIONAL AG (CH) | 2015-04-14 | — | — | US | claimed |
| EP-2605772-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | claimed |
| US-20130149751-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNATIONAL SA (CH) | 2013-06-13 | — | — | US | claimed |
| WO-2012024100-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | claimed |
| EP-2605772-B1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNAT AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-20150259284-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNATIONAL SA (CH) | 2015-09-17 | — | — | US | disclosed |
| US-9006460-B2 | Process for preparing aminocyclohexyl ether compounds | CARDIOME INTERNATIONAL AG (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-2605772-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130149751-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME INTERNATIONAL SA (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024100-A2 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259284-A1 | PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS | CYP3A43, CYP4B1, CYP3A4 | SLC6A4 2792/4885KCNA5 1842/4885SCN5A 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.